OncoMatch/Clinical Trials/NCT07022535
Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
Is NCT07022535 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Carboplatin plus Paclitaxel for ovarian cancer.
Treatment: Carboplatin plus Paclitaxel — About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: neoadjuvant chemotherapy
Exception: those who have just had one cycle within 21 days and the baseline CA125 is available
Patients who have already started NACT outside the study centres, except those who have just had one cycle within 21 days and the baseline CA125 is available.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify